Plus   Neg

Stock Alert: BioCryst Shares Climb In Pre-Market After Reporting Q4

Shares of BioCryst Pharmaceuticals Inc. (BCRX) are rising above 8% in pre-market today, after the company reported Q4 results. The stock has been trading between $1.38 and $9.26 in the past one year, and closed Wednesday's trading session at $3.51, up 37 cents or 11.78%.

Q4 Results

Net loss for the fourth quarter of 2019 was $2.6 million, or $0.02 per share, compared to a net loss of $27.4 million, or $0.25 per share, for the fourth quarter of 2018.

Total revenues were $39.7 million, higher than the previous year's $2.7 million, largely due to the recognition of $20.1 million of the $22.0 million upfront payment from Torii for commercialization rights in Japan for berotralstat for the prevention of HAE attacks, and $13.9 million of RAPIVAB (peramivir injection) product sales under the company's procurement contract with the Centers for Disease Control.

The company also announced that first patients have been dosed with BCX9930 in a proof of concept trial in paroxysmal nocturnal hemoglobinuria (PNH). These patients were naïve to eculizumab and ravulizumab.

BCX9930 is an oral Factor D inhibitor discovered and developed by BioCryst for the treatment of complement-mediated diseases. The company expects to report data from the proof of concept study in PNH patients in the second quarter of 2020.

Also, the company announced PDUFA date of December 3, 2020 for approval and launch of oral, once-daily berotralstat in U.S.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT